BioAtla
BCAB
73 hedge funds and large institutions have $208M invested in BioAtla in 2022 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 20 increasing their positions, 22 reducing their positions, and 25 closing their positions.
360% more call options, than puts
Call options by funds: $3.34M | Put options by funds: $726K
211% more capital invested
Capital invested by funds: $67.1M → $208M (+$141M)
0.18% more ownership
Funds ownership: 1.31% → 1.49% (+0.18%)
9% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 22
4% less funds holding
Funds holding: 76 → 73 (-3)
12% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$13.2M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$10M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$5.2M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.01M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$3.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$9.2M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.94M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$2.35M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.94M |
| 5 |
Two Sigma Investments
New York
|
-$1.49M |
BCAB Hedge Fund Activity: Q3 2022 in Review
73 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in BioAtla (BCAB) for Q3 2022, worth a combined $208M — up 211% from $67.1M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of BCAB and 22 opened new positions — a net loss of 3 holders — while 22 trimmed existing stakes and 20 added.
The largest buyer was Janus Henderson Group, adding an estimated $13.2M. The largest seller was Tang Capital Management, cutting an estimated $9.2M.
- 73 institutional investors held BioAtla (BCAB) as of Q3 2022, down from 76 in Q2 2022.
- Funds reported $208M of BioAtla stock for Q3 2022, up 211% quarter-over-quarter.
- 22 funds opened new BioAtla positions in Q3 2022 and 25 closed out, a net change of -3 holders.
- The largest BioAtla buyer in Q3 2022 was Janus Henderson Group, an estimated $13.2M added.
- The largest BioAtla seller in Q3 2022 was Tang Capital Management, an estimated $9.2M sold.
Based on aggregated 13F filings for Q3 2022.